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Abstract
The versatility of sortase-mediated ligations as a protein modification technique
has been well demonstrated, but the efficiency of these reactions suffers from inherent
reversibility. Solutions to this issue have been reported, however these methods are
accompanied by additional limitations of the sortase-mediated ligation (SML) strategy. A
preferable methodology would include the smallest possible modification site without
restricting the point of ligation. One promising solution to this issue is the expansion of
the LPXTG SrtA recognition sequence to LPXTGGH, giving the excised fragment an Nterminal GGH motif. This minor alteration has been shown to allow complexation of the
excised fragment with Ni2+ ions, thus sequestering this component from the reaction and
improving yields through hindered reversibility. In this thesis, we explore the scope of this
metal-assisted sortase-mediated ligation (MASML) approach, including the Ni2+enhanced modification of full sized proteins with a number of useful chromophores.
Furthermore, this approach was shown to be compatible with the installation of PEG and
a cyclooctyne bioorthogonal ligation handle. In total, this work demonstrates that MASML
is compatible with a range of high value protein targets and modifications, and shows how
MASML is a straightforward method for improving the efficiency of sortase-mediated
protein engineering strategies.
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1. Introduction
1.1 Overview of Protein Engineering Techniques
The use of protein engineering to generate molecules with novel functionality is an
ever-growing field of research, with academic, industrial, and medical applications.
Techniques vary, with the most basic being molecular biology techniques to modify
proteins on a genetic level. Simple point mutations, sequence deletions and additions1
are all useful for investigating protein structure and function, but the dependence on
rational design as well as typically being restricted to naturally occurring amino acids,
imposes a limitation on the type of alterations one can make to protein structures. Great
strides have been made to circumvent these limitations, notably in the areas of directed
evolution2–4 and unnatural amino acid mutagenesis5–8. However, these techniques
remain time consuming and expensive, and thus there continues to be a need for
complementary protein engineering techniques.
In contrast to genetic approaches, direct chemical modification of proteins provides
a quick and experimentally facile way to access altered protein structures. By taking
advantage of the natural chemistry of amino acid side chains such as cysteine, lysine,
glutamic and aspartic acids, one can append non-natural modifications to an already
properly folded protein structure. This has been used for chromophore-9 and radiolabeling,10 the attachment of drugs in the context of therapeutics,11 and the introduction
of structures to improve half-life and solubility in vivo.12,13 For example, the modification
of lysine residues is one of the most widely used forms of chemical-based protein
modification, performed by introducing reagents consisting of a desired modification,
tethered to an amine-reactive functional group such as an N-hydroxysuccinimidal ester.

Lysine side chains are able to act as nucleophiles, resulting in the covalent attachment of
the desired functional group. Reagents for the selective modification of cysteine, aspartic
and glutamic acid, and a range of other amino acids are also readily available.14 However,
these reactions generally lack site-selectivity. While the reagents used can differentiate
between the types of side-chains, it is difficult to distinguish between copies of the same
residue. Therefore, these techniques typically lead to polydisperse, non-specific
modifications. While this heterogeneity may be permissible for applications such as
fluorescent protein labeling, it may be incompatible with more demanding applications
such as the production of defined protein-drug conjugates.
More recently, chemoenzymatic approaches have emerged that combine the most
desirable attributes of genetic and chemical methods for protein engineering.15
Chemoenzymatic strategies take advantage of the pre-existing protein modification
activity of enzymes, which have evolved to recognize specific amino-acid sequences
within their complementary substrates (Figure 1). When these substrates are
incorporated into protein targets of interest, the corresponding enzyme can then be used
to site-specifically install useful modifications. By enabling a wide range of useful
transformations on an even wider range of targets, enzymes provide a library of natural
tools for modification chemistry. Chemoenzymatic techniques therefore provide
advantages over traditional protein engineering approaches, specifically in the ability to
generate consistent, monodisperse constructs, by virtue of the genetically encoded
recognition sequence.
These methods also allow for considerable flexibility in the types of modifications
installed, as many enzymes used in chemoenzymatic approaches can utilize diverse
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synthetic small molecule reagents, so long as they contain the appropriate molecular
features required for recognition by the enzyme. Advances in screening techniques have
also lead to the directed evolution of enzymes with a broadened scope of targets and
allowable modifications.16,17 Enzymatic processes can also be manipulated in vitro to
allow for the site-specific installation of short peptides or synthetic chemical modifications
such as chromophores,18–22 click handles,23–26 or pharmaceuticals.27
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Lipoic Acid
ATP

Biotin
ATP

CXPXR
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TGase

GLNDIFEAQKIEWHE

PNPQLPF

Figure 1. Representative chemoenzymatic approaches for protein modification.

Examples of enzymes used for chemoenzymatic protein labeling include formyl
glycine generating enzyme,28 which converts cysteine residues to aldehydes for further
bioconjugation with aminooxy and hydrazide reagents; transglutaminase, 29 used for the
crosslinking of glutamine with lysine sidechains or other free amines; biotin 30 and lipoic
3

acid ligases,31 which append their respective modifications to lysine sidechains through
the hydrolysis of ATP; and the bacterial sortases,32–36 transpeptidases which cleave their
target sequence and append modifications to the protein termini.

1.2 Adapting Sortase A for Chemoenzymatic Protein Labeling
First characterized by Schneewind and colleagues in 1999,35 sortase enzymes
were discovered in the cell walls of most gram-positive bacteria, and to date six classes
(A-E) of these enzymes gave been described.33 Class A (SrtA), the most thoroughly
characterized of the sortase family, consists of ‘housekeeping’ enzymes which aide in the
incorporation of numerous proteins, including virulence factors, into the bacterial cell
wall.35 Class B attach heme-receptors to peptidoglycans,37 and participate in the
construction of bacterial pili.38 Class C are also involved in pilus formation and are
noteworthy for their ability to form isopeptide bonds.39,40 Class D is found predominantly
in Bacilli and has been implicated in the anchoring of cell wall proteins which allow for
bacterial sporulation.41 Comparatively little is known about classes E and F, though the
class F sortase found in Corynebacterium diptheriae has been shown to perform
housekeeping functions similar to SrtA.42
Sortases, while interesting in their importance to the virulence of pathogenic
bacteria, have also proven useful as tools for protein modification.23,43 In vivo, SrtA from
S. aureus (SrtAStaph) specifically has been frequently used as a chemoenzymatic
approach for protein modification, and sortase-mediated ligation (SML) is now a widely
used technique. SrtA acts by recognizing an LPXTG motif (where X can be any amino
acid) and cleaving between the threonine and glycine residues (Figure 2). This is
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achieved through nucleophilic attack of the amide bond by a highly conserved active-site
cysteine. The glycine and remainder of the target molecule’s C-terminus becomes what
will heretofore be termed the “excised fragment”, while the N-terminal portion of the
substrate remains covalently linked to the sortase enzyme. The resulting thioester bond
is then itself susceptible to nucleophilic attack by an N-terminal glycine residue, yielding
the final ligation product. The sorting-sequence containing molecule is often a nascent
virulence factor, while the nucleophile is the pentaglycine head of lipid II, a cell wall
precursor. However, this reaction can also be performed in vitro with a variety of ligation
partners, including live cells,19–21 solid supports,44 full sized proteins,18,23–25,27,44
chromophores18,20–22,45 and other small molecule modifications46 (Figure 3). It should be
noted, recombinant SrtAStaph requires Ca2+ for optimal activity in vitro.
NH2
NH2

L
P
X
T

NH2

L
P
X
T
G

S

SH
G
SrtA

GGGGG

SrtA

Figure 2. Sortase A-mediated cell wall anchoring in vivo.
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(protein / synthetic
peptide)

-LPXT(G)n-
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LPXTG substrate
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peptide)

Label

sortase A
S. aureus

Figure 3. General ligation mechanism of sortase A.

Example applications of SML include the generation of antibody drug conjugates
(ADCs), as was shown by Beerli et al. in 2015.27 Their group demonstrated how SMLgenerated equivalents of commercial ADCs such as the anti-CD30 brentuximab vedotin
(Adcetris) and anti-HER-2 trastuzumab emtansine (Kadcyla) performed identically to the
traditional constructs during in vitro assays. The sortase-generated trastuzumabmaytansine was also shown to have similar activity to Kadcyla in mice models. Another
study by the Park group examined the use of SML for the direct labeling of live cells by
introducing sortase-ready fluorescent markers (EGFP-LPETG5 and TAMRA-LPETG5) to
HeLa cells expressing SrtA on their surface.20 These cells were shown to fluoresce, due
to the formation of a conjugate between the fluorescent substrates and the sortase
molecules, while controls treated with non-compatible substrates (EGFP-LPETA5 and
TAMRA-LPATA5) did not form the conjugate, and therefore did not exhibit fluorescence.
In addition to applications for direct conjugation chemistry, SML can also be used to
introduce secondary conjugation sites for additional biorthogonal modifications, such as
the incorporation of click handles. Krueger et al. demonstrated the benefits of this method
6

by using SML to introduce tetrazine- and alkene-baring linkers of varying lengths to
protein ligands which were further conjugated together via a bioorthogonal click
reaction.25 This provided a simplified method of testing variable linker lengths, as it
allowed for the use of the same sortase-ready protein substrates, with alterations only
being required of the small synthetic linkers. In total, these studies exemplify some of the
common uses of SML as a protein modification technique.
The sortase enzyme itself has also been modified to better suit in vitro applications.
As indicated above, a commonly used and well characterized form is the SrtA homolog
from Stapholococcus aureus, SrtAStaph. The enzyme is typically used in a truncated
mutant form (Δ59), lacking the first 59 amino acid residues, which correspond to the
transmembrane domain which would anchor sortase in vivo. This truncation allows for
SrtAStaph to be expressed in soluble form and used effectively in aqueous solutions
(Figure 3). A further mutant, designed to not possess a typical N-terminal glycine, is also
used to prevent non-target interaction of the acyl-enzyme intermediate with a second
sortase enzyme acting as a nucleophile.
Further modification was performed to the enzyme in 2011 through directed
evolution using yeast display to select for mutations which increased reaction kinetics
through improved substrate binding.47 The end result was a penta-mutant SrtAStaph
(SrtA5mut) with improved binding affinity for both LPXTG and N-terminal glycine
substrates, and a 120-fold increase in kcat/KM. In 2012, another study showed how Ca2+independence could be achieved through the mutation of two glutamates within the
calcium-binding pocket of SrtAStaph.48 However, these mutations proved to be detrimental
to the overall activity of the enzyme, which showed a more than 3-fold decrease in kcat.
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Hirakawa et al., who originally demonstrated these effects, later combined these two
mutations with those of the penta-mutant, in the hopes of improving kinetics while
maintaining Ca2+ independence. The resulting hepta-mutant (SrtA7mut) exhibited an 8-fold
increase in kcat/KM LPETG and a 4-fold increase in kcat/KM GGG.48 Both the penta- and heptamutants provide improvements to the typical SML reaction and have been used to
perform faster and more efficient ligations than achievable with wild-type SrtAStaph.

1.3 Current Techniques for Limiting Reversibility of the Sortase Reaction
While a widely used ligation technique, like most enzymatic methodologies sortase
has its limitations. In the case of SML, the inherent reversibility of the reaction is a
frequently cited drawback.43 As mentioned previously sortase acts by first recognizing an
LPXTG motif in its target substrate, but this sequence is also present in the final ligation
product. This allows the product to be recognized by the sortase enzyme, and in turn
causes cleavage of the desired modification and replacement by the initial excised
fragment. Overall, this results in regeneration of starting substrate protein and the initial
glycine nucleophile. For this reason, most sortase-mediated ligations performed with
equimolar concentrations of substrate and nucleophile typically reach only 50%
completion.
To improve ligation efficiency, a growing number of solutions have been described.
The most straightforward of these is to include an excess of one of the ligation partners.
This drives the reaction equilibrium towards products and increases yields accordingly,
however this is not ideal if the reagents being used in excess are either costly, difficult to
prepare, or difficult to remove from the final reaction mixture.
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More modern methods for controlling the reaction equilibrium have focused on
deactivating certain products of the SML reaction, preventing them from re-entering the
catalytic cycle. The first of these methods for enhancing ligation efficiency was introduced
by Yamamura and colleagues and involves inducing the formation of a β-hairpin upon
ligation (Figure 4).49 This is achieved by incorporating Trp-Thr repeats upstream of the
sorting sequence of the substrate and downstream of the nucleophile’s N-terminus. Upon
ligation a ‘Trp zipper’ is formed, effectively hindering interaction of the reformed LPXTG
motif with the SrtA active site. Using equimolar concentrations of the starting materials,
yields were improved from 50% to ~70%, over the course of a 24hr reaction. The ligation
products were also shown to have long-lasting resistance to SrtA cleavage, even in the
presence of excess triglycine nucleophile. While effective at improving yields, the
introduction of secondary structure around the ligation site, and the expansion of the
ligation site itself, is not ideal, as one begins to risk interference with the folding and
function of the desired protein ligation product.
β-hairpin unrecognized
by Sortase A

Protein 1 -WTWTW-LPATGG

Protein 1 -WTWTW-L

P
A
T
G
Protein 2 -WTWTW-G

Sortase A
+

H2N-GG-WTWTW- Protein 2

+ H2N-GG

~70% conversion

Figure 4. Ligation product deactivation technique described by Yamamura et al. for the
improvement of SML yields.49
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In addition to β-hairpins, other techniques take advantage of deactivated excised
fragment molecules, specifically by reducing the nucleophilicity of these species.
Williamson et al. achieved this by generating synthetic depsipeptide substrates containing
an unnatural diglycine mimic within the LPXTG sequence (Figure 5a).43 The substrate,
which has an ester in place of the native Thr-Gly amide bond, produces an N-terminal
hydroxyl group upon cleavage. This is a considerably weaker nucleophile compared to
the amine of an N-terminal glycine and prevents the alcohol by-product from participating
in a reverse ligation reaction. Similarly, Liu et al. showed that by incorporating isoacyl-Ser
or isoacyl-Hse two residues downstream of the recognition sequence, a spontaneous
diketopiperanzine formation deactivates the excised fragment, thus favoring product
formation (Figure 5b).50 Both strategies require the substrates to be produced through
solid-phase peptide synthesis, thus limiting modifications to the N-terminus of protein
targets.
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Sortase A
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H
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O

KYALPETGG- Protein

OH

O

quantitative conversion

diglycine mimic

B

Figure 5. Nucleophile deactivation techniques proposed by Williamson et al.43 (A) and Liu et al.50
(B) for the improvement of SML yields.

Given the limitations of the previous strategies for boosting SML efficiency, we
sought to develop a new approach which would ideally (1) maintain the minimal size of
the SML ligation site (LPXTG), (2) be applicable to a broad range of SML applications
involving modification of the protein N- or C-terminus, and (3) not require significant
synthetic modification of the peptide modifying agents generally used for SML.
Additionally, the technique should allow for high ligation yields in idealized, equimolar
substrate conditions, to make the reaction as cost effective and efficient as possible.
A strategy meeting these criteria was introduced by Row et al., who proposed that
by the simple expansion of the sortase recognition sequence to LPXTGGH, the excised
fragment would be capable of coordinating with Ni2+ via the new N-terminal GGH motif
11

(Figure 6).51 The metal-peptide complex, anchored through the histidine residue, was
shown to effectively sequester the nucleophilic lone pair of the N-terminal glycine,
reducing the overall nucleophilicity of the excised fragment.

LPXTGGH + NH2-GG

SrtA
Ni2+

Nitrogen lone pair
sequestered by Ni2+

LPXTGG +

Histidine “anchors”
complex

Figure 6. Structure of the complex formed between Ni2+ and the N-terminus of the GGH excised
fragment.

In contrast to previous methodologies for improving SML efficiency, this approach
to deactivating one of the ligation products does not require changes to the size of the
final sortase ligation site or the use of complex synthetic substrate mimetics. Moreover,
the expanded recognition sequence includes no non-natural amino acids and can
therefore be synthesized by standard solid phase peptide synthesis (SPPS) or encoded
into protein targets at the genetic level. In the initial report, this technique was
demonstrated most thoroughly in the context of small peptide substrates and
nucleophiles, with ligation yields improved from 60% to over 80% when working at
equimolar concentrations (Figure 7).51 While effective with peptides, the application of
this metal-assisted sortase-mediated ligation (MASML) approach to larger protein targets
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was minimal and involved only two examples focused on the C-terminal modification of
maltose binding protein and the N-terminal modification of insulin.

SrtAstaph

GK(Dns)
±Ni2+
Ac-K(DNP)LPETGGHG

Ac-K(DNP)LPETGK(Dns)
- Ni2+: 60%
+ Ni2+: 80%

Figure 7. Example MASML reaction performed on small molecule reagents by Row et al.51

1.4 Project Goals and Overview
The applicability of metal-assisted sortase-mediated ligation (MASML) to the
modification of full-sized proteins has not been as thoroughly studied as small peptide
applications. Given the prevalent use of sortase as a protein modification tool, it was
therefore made the goal of this project to demonstrate a fuller scope of protein
applications for MASML, using a variety of protein targets in conjunction with a range of
industrially and medically relevant protein modifying agents.
To this end, this thesis describes the expression and purification of multiple small
protein targets which represent alternative, non-antibody scaffolds for molecular
recognition. These proteins were prepared with a MASML-expanded SrtA recognition
sequence (LPETGGH), with the histidine being the first residue of a standard C-terminal
His6 affinity tag. Notably, this sequence is common in sortase-ready protein substrates
which have been reported in the literature.18,19,22,23,26,44,46,52 A suite of small peptide
nucleophiles was also generated, equipped with a range of protein modifiers including
fluorophores, PEG, and a bioorthogonal reaction handle. With these materials, we have
succeeded in demonstrating how MASML is compatible with numerous model protein
13

modification reactions, resulting in significant improvements in ligation efficiency when
reactions were conducted in the presence of Ni2+ ions. In addition, we have shown how
MASML reactions under equimolar reagent concentrations outperform non-MASML
reactions employing excess reagents, and demonstrated how secondary bioorthogonal
ligation reactions can be performed on MASML products without the need for intermediate
purification steps.
In total, these studies demonstrate how MASML is an effective and easily
implemented strategy for improving SML methodology.

2. Preparation of Protein Targets and Peptide Nucleophiles
2.1 Design, Expression and Purification of MASML Protein Substrates
As described above, the intention of this study was to demonstrate the applicability
of MASML to full size protein targets. To this end, we identified a variety of small protein
targets to use as MASML substrates. The panel of chosen substrates included DARPin
and affibody molecules, both with high HER2 binding affinity.53,54 The DARPin (designed
ankyrin repeat protein) structure is based on the common ankyrin repeat motif which
facilitates protein-protein interactions through the loops between helices (Figure 8a), and
can be specifically engineered to bind a wide range of complementary antigens.55
Affibody molecules (Figure 8b) are based on the immunoglobulin G binding domain of
protein A, and can be given novel binding specificity via directed evolution, similar to
DARPin.56 This study also included a monobody molecule specific for YES1,57 a tyrosine
kinase involved in the regulation of cell growth and survival; as well as a fynomer
complementary to a serine protease chymase involved in allergic reactions.58
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Monobodies (Figure 8c) are another type of antibody mimetic, built using the fibronectin
type III domain as a scaffold.59 Fynomer (Figure 8d) is based on the SH3 domain of the
tyrosine-protein kinase Fyn, which is generally associated with cell signaling. 60 The final
substrate used in this thesis was a commercially available solubility tag, Fh8,61 equipped
with a MASML-compatible linker.
In all cases other than Fh8, protein targets were examples of non-antibody
scaffolds for molecular recognition and are regarded as promising alternatives to full size
antibodies for the development of therapeutics and basic research tools. 62 Notably, SML
has previously been shown to be an effective tool for appending secondary functionality
to antibodies, including fluorophores and therapeutics.9,11,18,27,44 The rising interest in
non-antibody scaffolds therefore makes these proteins high value targets for the
development of site-specific modification strategies such as MASML.
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A

B

C

D

Figure 8. Crystal structures of the protein substrates used in this study. (A) DARPin with affinity

for HER2, PDB: 2JAB. (B) Affibody with affinity for HER2, PDB: 2KZJ. (C) Fynomer with
affinity for serine protease chymase, PDB: 4AFS. Monobody with affinity for YES1, PDB:
5MTJ.
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To render the protein targets compatible with MASML, all proteins were produced
with sortase-ready C-termini, containing a short spacer ((G4S)2) followed by the sortase
recognition sequence (LPETGG), and ending in a His6 tag (Figure 9). This arrangement
allows for nesting of the nickel-binding GGH motif directly into the sortase and His6 sites.
Plasmids encoding these constructs were obtained via commercial gene synthesis. To
designate the presence of the sortase-ready C-termini, these protein substrates are
hereafter designated sDARP, sAff, sMon, sFyn and sFh8.
nickel
coordination
motif

spacer
sequence

Protein -(GGGGS)2-LPETGGHHHHHH
SrtAstaph
recognition
sequence

affinity
purification
tag

Figure 9. General structure of MASML-compatible protein substrates used in this study.

The plasmids were transformed into BL21(DE3) E. coli cells and protein production
was performed using standard IPTG-induced overexpression. After lysing the cells and
separating out the protein containing lysate, all proteins were purified using the same two
step method. First, the proteins were IMAC purified on a gravity flow-based Ni-NTA
column to remove the majority of contaminants. The elutions were then desalted using
an FPLC system, and the fractions combined for a secondary IMAC purification step. This
second IMAC step was found to remove non-target protein contaminants, but the main
purpose was to separate out truncated variants of the target proteins. These variants
typically lacked two of the histidines from the His6-tag and were visible in post-desalting
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analysis via ESI-MS (Figure 10). These His4 proteins could be separated by FPLC-based
Ni-NTA purification, using a controlled gradient of imidazole buffer to elute the variants at
different times. Fractions were examined using ESI-MS and those containing only His6
were combined and desalted. Final ESI-MS analysis revealed proteins of at least 95%
purity in all cases, at which point the substrate proteins were ready for use in MASML
reactions (see Appendix III for analytical ESI-MS spectra and SDS-PAGE of each protein
stock solution).

Intensity

15550 Da

15276 Da

A
14000

15318 Da
15591 Da
Mass (Da)

16500

Intensity

15550 Da

B

15275 Da

14000

Mass (Da)

15590 Da
16500

Figure 10. ESI-MS spectra of sDARP after the first (A) and second (B) IMAC purification steps.
Expected mass for the full protein was 15550 Da, while the His4 variant had an expected mass of
15276 Da. Minor contaminants including the addition of ~40-42 Da are postulated to correspond
to acetylated protein derivatives.
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2.2 Synthesis of MASML-Compatible Nucleophile Library
Similar to the protein substrates, the nucleophile library generated for this research
was created with a focus on installing modifications of proven industrial and medical use.
To begin with, three common fluorophores were selected: 6-carboxyfluorescein (6-FAM),
cyanine-3 (Cy3), and 7(diethylamino)courmarin-3-carboxylic acid (DEAC). In addition, a
branched polyethylene glycol chain with a discrete mass of 2190 Da (dPEG2000) was
used as well. The final modification was an established click-handle, dibenzocyclooctyne
(DBCO). These functional groups were chemically appended to the lysine side-chain of
a small base peptide, generated through standard solid phase peptide synthesis (SPPS)
methods. The base peptide had the sequence GGK for all nucleophiles except the
PEGylated variant, which contained an additional tyrosine residue for quantification, as
PEG does not possess an easily quantified chromophore. The full structure of all MASMLcompatible peptides used in this thesis are given in Figure 11.
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GGK6-FAM

Figure 11. Structures of nucleophiles and appended modifications used in this study.

The preparation of all nucleophiles was achieved using a similar strategy. As
illustrated in Figure 12, a base peptide was first generated by SPPS and then cleaved
from the resin without a final deprotection step so as to leave the N-terminus Fmocprotected. The identities of the base peptides were confirmed by ESI-MS. Crude peptide
solutions were then combined with the desired modification, activated as the
corresponding N-hydrozysuccinimide (NHS) ester or tetrafluorophenol (TFP) ester. A 2fold molar excess of the base peptide was employed to ensure complete consumption of
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the activated esters. These coupling steps were monitored using ESI-MS (Figure 13),
and upon completion, piperidine was added to remove the Fmoc group, deprotecting the
N-terminus. Final nucleophile products were purified using by RP-HPLC. Product identity
and purity were confirmed using ESI-MS and HPLC analysis, respectively (Appendix II).
The completed nucleophiles were quantified using the extinction coefficient of their
respective functional groups (tyrosine in the case of GGKdPEG2000Y). Approximately 1mM
stocks of each nucleophile were prepared for use in later MASML reactions.

Piperidine
(20%)
NMP

Fmoc-protected
AAs
HBTU, DIPEA

TFA

20%
Piperidine

R—active
ester
DIPEA

Figure 12. Representative synthesis scheme for the generation of peptide nucleophiles used in
this study.
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Fmoc-GGKDBCO

Fmoc-GGK

20%
Piperidine

NHS-DBCO

A

GGKDBCO

C

B

Figure 13. Representative ESI-MS spectra for the synthesis of GGKDBCO: (A) Fmoc-GGK base
peptide, (B) ligation of Fmoc-GGK with NHS-DBCO, (C) final ESI-MS analysis of the GGKDBCO
stock following Fmoc deprotection and HPLC purification. Expected [M+H]+ values: Fmoc-GGK =
482.2 Da, Fmoc-GGKDBCO = 769.3 Da, GGKDBCO = 547.3 Da.

3. Results
3.1 C-terminal Fluorophore Labeling of DARPin
With all necessary reagents in hand, we proceeded to investigate the compatibility
of MASML with different protein targets and modifications. In all cases, it was anticipated
MASML would give significant improvements in ligation efficiency when equimolar
concentrations of the protein substrates and glycine nucleophiles were combined in the
presence of a Ni2+ additive. Furthermore, we sought to demonstrate these MASML
reactions would significantly outperform the corresponding control reactions lacking Ni2+.
To begin, we established a standard set of reaction conditions consisting of 50µM
of each ligation partner, and 10 µM SrtAStaph (Figure 14). For Ni2+, a 4-fold molar excess
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(relative to protein substrate) of NiSO4 was found in preliminary studies with sDARP to
give significant improvements in sortase-mediated ligation conversion with no apparent
deleterious effects on protein solubility. Higher Ni2+ concentrations were prone to protein
precipitation and failed to further improve ligation efficiency. All reactions were conducted
at room temperature.

SrtAstaph

ProtS —LPETGGH6

GGK(R)
±Ni2+

ProtS —LPETGGK(R)

Figure 14. Overview of C-terminal modification via MASML.

Conjugation of sDARP and GGK6-FAM. In the initial reaction system, the C-terminal
modification of sDARP with GGK6-FAM was performed in the presence or absence of Ni2+
and monitored over the course of 9 hours (Figure 15a). All reactions were performed in
duplicate and monitored using ESI-MS to track the relative concentrations of unmodified
starting material and conjugated product. Reconstructed mass spectra were used to
estimate the relative amounts of all proteins species, including any hydrolyzed starting
material arising from hydrolysis of the acyl-enzyme intermediate (Figure 15).
The (-)Ni2+ reactions reached completion at 6 hours, and achieved a maximum
conversion of 41%, while the (+)Ni2+ reactions reached completion at 8 hours, with a final
conversion of 84%. Hydrolysis was observed to increase for the (+)Ni2+ reactions, with an
increase from <1% to 9.5% with the addition of Ni2+.
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Figure 15. ESI-MS time course data for the C-terminal modification of sDARP with GGK6-FAM. (A)
Product conversion for both reactions as estimated by ESI-MS. All data points represent the mean
of duplicate trials, with error bars corresponding to the full range of the data set. (B) ESI-MS
spectra from the 9hr timepoints of the (+)Ni2+ (bottom) and (-)Ni2+ (top) reactions (calculated
molecular weights: sDARP = 15550 Da, sDARP(6-FAM) = 15213 Da, hydrolyzed sDARP = 14613
Da).

Conjugation of sDARP and GGKCy3 / GGKDEAC. To evaluate compatibility with other
fluorophores, we proceeded to investigate the ligation of GGKCy3 and GGKDEAC using the
same DARPin substrate. Reactions were identical to those described above, and were
monitored by ESI-MS over the course of 9 hours. Interestingly, in the case of Cy3 the
(-)Ni2+ reactions performed surprisingly well, and reached completion at 7 hours with a
maximum product conversion of 77% (Figure 16a). The (+)Ni2+ reactions did give
improved results, reaching completion at around 8 hours, with a final conversion of 95%
(Figure 16b). Hydrolysis was only minorly enhanced in the (+)Ni2+ reactions, with an
increase from <0.5% to ~1% (estimated by mass spectrometry) with the addition of Ni2+.
While the enhancement provided by Ni2+ was less pronounced for this reaction than for
the ligation of sDARP and GGK6-FAM, there was no overlap in the two datasets, implying
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some enhancing effect by Ni2+ on the reaction efficiency. This reaction may simply
represent a case where the ligation equilibrium is inherently biased towards products,
potentially due to the properties of the Cy3 dye. This phenomenon was not investigated
further.
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Figure 16. ESI-MS time course data for the C-terminal modification of sDARP with GGKCy3. (A)
Product conversion for both reactions was estimated by ESI-MS. All data points represent the
mean of duplicate trials, with error bars corresponding to the full range of the data set. (B) ESIMS spectra from the 9hr timepoints of the (+)Ni2+ (bottom) and (-)Ni2+ (top) reactions (calculated
molecular weights: sDARP = 15550 Da, sDARP(Cy3) = 15291 Da).

Moving on to the ligation of the DEAC-functionalized nucleophile, Ni2+ was once
again found to significantly improve reaction efficiency when monitored over the course
of 12 hours (Figure 17a). The (+)Ni2+ trials were observed to run at a slower initial rate
than the (-)Ni2+ reactions, unlike the previous MASML reactions performed for sDARP
with GGK6-FAM and GGKCy3. The (+)Ni2+ reactions were therefore repeated (4 trials total)
to confirm this trend, which was observed in all trials including Ni2+. Despite this initial
delay in reaction progress, ligation in the presence of Ni2+ ultimately provided superior
reaction conversions. Specifically, the (-)Ni2+ reactions reached completion at 9 hours and
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achieved a maximum product conversion of 65%, while the (+)Ni 2+ reactions were
seemingly still slowly proceeding at 12 hours, having reached a conversion of 94%
(Figure 17a). Hydrolysis was minimal in all reactions, reaching a maximum of 2.5% when
ligations were run in the presence of Ni2+.
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Figure 17. ESI-MS data for the C-terminal modification of sDARP with GGKDEAC. (A) Product
conversion for both reactions was estimated by ESI-MS. All data points represent the mean of
duplicate trials, with error bars corresponding to the full range of the data set. (B) ESI-MS spectra
from the 12hr timepoints of the (+)Ni2+ (bottom) and (-)Ni2+ (top) reactions (calculated molecular
weights: sDARP = 15550 Da, sDARP(DEAC) = 15098 Da, hydrolyzed sDARP = 14613 Da).

Comparison of MASML to SML with Excess Reagent Loading. To further
demonstrate the enhancement of ligation efficiency provided by MASML, we next
compared the results of ligations using a MASML approach to those of a standard SML
strategy in which excess glycine nucleophile was used to drive the reaction to completion.
To this end, the SML reaction of sDARP and GGK DEAC in the absence of Ni2+ was
investigated using varied loadings of nucleophile (2, 3, 5 and 20 molar equivalents). The
reactions were monitored over the course of 11 hours, and the results were compared to
the initial (+)Ni2+ and (-)Ni2+ trials for equimolar concentrations of starting material (Figure
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18a). Remarkably, even with a 20-fold excess of GGKDEAC the reactions lacking Ni2+ failed
to outperform the corresponding MASML reaction using only 1 molar equivalent of
GGKDEAC. Specifically, the MASML reaction with one equivalent of GGK DEAC gave
conversions of ~93% at the 11hr timepoint, while the (-)Ni2+ reaction with 20 equivalents
of GGKDEAC reached ~90% (Figure 18a). Ligation yields were continuously improved with
each consecutive increase in nucleophile concentration in the absence of Ni 2+, however
there was an gradual decrease in the enhancement effect of each additional equivalent
of nucleophile. For example, the increase in yields when going from 3x to 5x (3.7%) was
the same as the increase when going from 5x to 20x (3.6%). Overall, these results
showed the MASML approach significantly improved reaction efficiency, allowing for
reduced loading of the GGKDEAC nucleophile without negatively impacting the production
of ligation products.
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Figure 18. ESI-MS data for the C-terminal modification of sDARP with varied loadings of GGKDEAC
in the presence or absence of Ni2+. The reaction with Ni2+ was only performed using one equivalent
of GGKDEAC. (A) Product conversion as estimated by ESI-MS for all (-)Ni2+ reactions (1-20
equivalents of GGKDEAC as well as the original (+)Ni2+ reaction with one equivalent of GGKDEAC).
All data points represent the mean of two trials, with error bars corresponding to the full range of
the data set. (B) Hydrolysis product concentration averaged for the same data sets as in A.
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Hydrolysis was also affected by increasing the nucleophile concentration (Figure
18b). As the amount of nucleophile available increased, the amount of hydrolysis
decreased, likely due to the excess nucleophile outcompeting water for reaction with the
acyl-enzyme intermediate. Hydrolysis became negligible by 2 equivalents of GGK DEAC
(<0.5%) and was completely undetectable in reactions with 20 equivalents of GGK DEAC.
While the reactions containing Ni2+ did result in the highest levels of hydrolysis (~2%), the
MASML approach was clearly superior in terms of ligation product formation and
eliminated the need for excess nucleophile in the ligation reaction (Figure 19).
95
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Product (%)

85
80
75
70
65
60
1x +Ni
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3x
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20x

Figure 19. Endpoint (11hr) product conversion amounts for the various (-)Ni2+ reactions (light gray
columns), compared to the initial (+)Ni2+ reactions using one molar equivalent of GGKDEAC (dark
gray column). Labels below chart indicate the equivalents of GGKDEAC used. Product formation
(%) was estimated by ESI-MS.

3.2 C-terminal Modification of Protein Substrates with DEAC
Conjugation of sAff and GGKDEAC. Having investigated the ligation of multiple
fluorophores to sDARP using MASML, we next turned our attention to other protein
targets, beginning with the C-terminal modification of sAff with GGKDEAC. Reactions were
performed in the presence or absence of Ni2+ for 12 hours and monitored by ESI-MS
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(Figure 20a). Surprisingly, sAff proved to be a poor substrate, with yields never exceeding
30% in either the presence or absence of Ni2+ (Figure 20a). Hydrolysis of sAff was not
detected for the (-)Ni2+ reaction, and did not exceed 0.5% with the addition of nickel. While
the reason for the poor reactivity of sAff remains unclear, we do note a similar affibodybased SML substrate has been described in the literature, and poor reactivity was
observed in this report as well.63 Therefore, the LPXTG substrate site on the affibody may
require additional engineering and optimization to improve reactivity. This substrate was
not investigated further.
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Figure 20. ESI-MS data for the C-terminal modification of sAff with DEAC. (A) Product conversion
for both reactions was estimated by ESI-MS. All data points represent the mean of duplicate trials,
with error bars corresponding to the full range of the data set. (B) ESI-MS spectra from the 12hr
timepoints of the (+)Ni2+ (bottom) and (-)Ni2+ (top) reactions (calculated molecular weights: sAff =
8714 Da, sAff(DEAC) = 8261 Da, sAff-His1 = 8027 Da).

Conjugation of sFyn and GGKDEAC. The C-terminal modification of sFyn with DBCO
was next analyzed in the presence or absence of Ni2+ for 12 hours (Figure 21a). The
(-)Ni2+ reaction reached completion at 8 hours and achieved a maximum product
conversion of 44%, while the (+)Ni2+ reaction reached completion at 9 hours, with a final
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yield of 94% (Figure 21b). Hydrolysis was negligible for both reactions, with
concentrations below 1% for the (+)Ni2+ reactions, and no detectable hydrolysis until the
11 hour timepoint of the (-)Ni2+ reactions.
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Figure 21. ESI-MS data for the C-terminal modification of sFyn with DEAC. (A) Product
conversion for both reactions was estimated by ESI-MS. All data points represent the mean of
duplicate trials, with error bars corresponding to the full range of the data set. (B) ESI-MS spectra
from the 12hr timepoints of the (+)Ni2+ (bottom) and (-)Ni2+ (top) reactions (calculated molecular
weights: sFyn = 10907 Da, sFyn(DEAC) = 10454 Da, putative acetylation of protein substrate
resulted in peaks of approximately +41 Da).

Conjugation of sMon and GGKDEAC. The C-terminal modification of sMon with
DEAC was investigated next. The sMon substrate proved to be somewhat more
challenging as the standard 4 molar equivalents of Ni2+ used for other protein targets led
to sMon precipitation. To circumvent this issue, we reduced Ni2+ to 2 equivalents, and
included 20% (v/v) DMSO to promote sMon solubility. ESI-MS analysis was also difficult
as sMon displayed low ionization efficiency, and so reactions were instead analyzed via
SDS-PAGE (Figure 22). Aliquots of the (+)Ni2+ or (-)Ni2+ reactions were collected at 0, 6,
12, and 24hrs and quenched with 4x DTT and SDS containing loading buffer. The (-)Ni2+
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reaction achieved a product conversion of 43% after 6 hours, and a maximum conversion
of 65% after 12hrs, while the (+)Ni2+ reactions reaction a conversion to product of 70%
by 6hrs, and a final yield of 85% at 12hrs (Figure 22). Hydrolysis was not detected for
either reaction. An additional reaction lacking both nickel and DMSO was run as a control.
This reaction progressed marginally faster than the (-)Ni2+ reaction, but did not exceed
the (+)Ni2+ reaction, with a 6hr yield of 61% and final yield of 68%. From this control
dataset we concluded the addition of DMSO likely slowed the overall rate of the reaction,
but likely did not impact the final yield amounts.
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 SrtA

 sDARP
 sDARP(DEAC)

 SrtA
 sDARP
 sDARP(DEAC)

Figure 22. SDS-PAGE gels for the C-terminal modification of sMon with DEAC. (Top) Lane 1
contains a molecular weight standard, lanes 2 and 3 contain standards of SrtAStaph and sMon
respectively, at reaction concentrations. Lanes 4-7: (+)Ni2+ reaction (20% DMSO) at 0, 6, 12, and
24hrs. Lanes 8-11: (-)Ni2+ reaction (20% DMSO) at 0, 6, 12, and 24hrs. (Bottom) Lane 1:
molecular weight standard; lanes 2-5: control reaction containing no Ni2+ and no DMSO, at 0, 6,
12 and 24hrs.

Conjugation of sFh8 and GGKDEAC. As a final protein target, we explored the Cterminal modification of sFh8 with GGKDEAC in the presence or absence of Ni2+ over the
course of 12 hours (Figure 23a). As observed in the case of sDARP and GGKCy3, the
(-)Ni2+ reactions were observed to be surprisingly successful and exhibited 79%
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conversion to the ligation product after 12 hours. While successful, the (-)Ni2+ reaction
was outperformed by the (+)Ni2+ system, which reached 96% conversion over the same
time period (Figure 23b). Hydrolysis was not detected for either reaction.

A

B

100

90

3.0E+09

80

% Product

4.0E+09

14231

14190

2.0E+09

70

1.0E+09

60
50

40

0.0E+00
13750

30

1.0E+10

20

8.0E+09

10

6.0E+09

14643

0

2

4

6

8

10

15000

14230

4.0E+09

12

14644

2.0E+09

Hours
-Ni

-Ni2+

14375

14189

0

14682

0.0E+00
13750

+Ni

14679

+Ni2+
14375

15000

Figure 23. ESI-MS data for the C-terminal modification of sFh8 with DEAC. (A) Product
conversion for both reactions was estimated by ESI-MS. All data points represent the mean of
duplicate trials, with error bars corresponding to the full range of the data set. (B) ESI-MS spectra
from the 12hr timepoints of the (+)Ni2+ (bottom) and (-)Ni2+ (top) reactions (calculated molecular
weights: sFh8 = 14636 Da, sFh8(DEAC) = 14183 Da, putative acetylation of protein substrate
resulted in peaks of approximately +41 Da).

3.3 C-terminal PEGylation of DARPin using MASML
To further investigate the scope of modifications that were compatible with
MASML, we evaluated the attachment of a branched, monodisperse PEG chain
(dPEG2000) to sDARP. The attachment of PEG and polymers using sortase has been
reported, and therefore this represents an important area of interest for users of sortasebased methods.64 As described in Section 2.2, the nucleophile for this application
contained a GGKY base peptide tethered to the branched PEG via an amide linkage to
the lysine side-chain. One molar equivalent of this nucleophile was combined with sDARP
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in the presence or absence of Ni2+ and monitored for 12 hours by ESI-MS (Figure 24a).
As anticipated, a marked improvement in ligation efficiency was observed when Ni2+ was
included. Specifically, the (-)Ni2+ reactions reached completion at 5 hours and achieved
a maximum conversion of 48%, while the (+)Ni2+ reactions reached completion at 10
hours, with a substantially improved final yield of 91% (Figure 24b). It should be noted
the ESI-MS signal for the PEG conjugated sDARP contained significant levels of
ammonium adducts, which has been observed previously for PEG conjugates. 65 The
signal from these ammonium adducts was included in the calculations for reaction
conversion. In addition to an increase in PEG attachment, hydrolysis was observed to
slightly increase for the (+)Ni2+ reactions, with an increase from <1% to 3.5% with the
addition of Ni2+.
These reactions were also examined by SDS-PAGE (Figure 25). Aliquots of the
(+)Ni2+ and (-)Ni2+ reactions were collected at 0, 4.5, and 9 hours and quenched by the
addition of reducing SDS-PAGE loading buffer. Samples were then analyzed by SDSPAGE along with control lanes containing SrtAStaph and unmodified sDARP (both at final
reaction concentrations). Relative band intensities from the Coomassie stained gel were
used to estimate product conversion at each time point. An improvement in reaction
conversion was observed when Ni2+ was included. The (-)Ni2+ reaction was finished by
4.5 hours with a maximum conversion below 50%, while the (+)Ni2+ reaction was still
progressing at 4.5 hours and had reached 70% conversion by the final timepoint. While
the conversion amounts calculated from the gel do not exactly match those seen in the
ESI-MS data, the overall trends remained consistent.
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Figure 24. (Top) Reaction scheme depicting the PEGylation of DARPin via MASML. (Bottom)
ESI-MS data for the C-terminal modification of sDARP with GGKdPEG2000Y. (A) Product

conversion for both reactions was estimated by ESI-MS. All data points represent
measurements averaged over two trials, with error bars corresponding to the full range of
the data set. The total signal for the sDARP(dPEG2000) conjugate was the summation
of the parent mass (M) as well as the observed ammonium adducts. (B) Example ESI-MS
spectra from the 12hr timepoints of the (+)Ni2+ (bottom) and (-)Ni2+ (top) reactions (calculated
molecular weights: sDARP = 15550 Da, sDARP(dPEG2000) = 17190 Da, hydrolyzed
sDARP = 14613 Da). (C) Close-up view of PEG conjugated sDARP from the (-)Ni2+ reaction
showing presence of ammonium adducts (+18 Da).
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Figure 25. SDS-PAGE analysis of the C-terminal modification of sDARP with dPEG2000, in the
presence or absence of Ni2+. Lane 1: Molecular weight standard with masses (kDa) labeled. Lane
2: Control containing only sDARP at 50µM. Lane 3: Control containing only SrtAStaph at 10µM.
Lanes 4-6: Timepoints for the (+)Ni2+ reaction. Lanes 7-9: Timepoints for the (-)Ni2+ reaction. Lane
10: Molecular weight standard. Percent conversion values, estimated from relative band
intensities, are indicated at the bottom of each lane.

3.4 Combined MASML and Bio-orthogonal Ligation
Bioorthogonal ligation reactions, or “click” reactions, have garnered significant
attention for their ability to facilitate rapid, covalent ligations, which can be performed on
organic and inorganic molecules alike, using mild reaction conditions.66,67 Copper-free
click chemistry is of particular import, as it eliminates the copper catalyst typically required
for azide-alkyne click reactions, which can be detrimental to live-cell applications. These
reactions occur in the absence of a catalyst by introducing strain to the alkyne, commonly
in the form of a cyclooctyne.68 When introduced into the same reaction mixture, the click
handles undergo a Huisgen cyclization to produce the ligation product (Figure 26). These

36

handles can be readily appended to proteins and peptides via NHS-ester chemistry, thus
allowing for the rapid generation of complex molecules.

Figure 26. Mechanism for the cyclization of a strained cyclooctyne and azide biorthogonal pair.

With this in mind, we next assessed whether MASML was compatible with a
representative bioorthogonal ligation system. To this end we explored the MASML using
sDARP and a nucleophile tethered to a strained cyclooctyne (GGKDBCO). Similar to the
reactions described above, The C-terminal modification of sDARP with GGKDBCO was
performed in the presence or absence of Ni2+ and monitored by ESI-MS for 9 hours
(Figure 27a). The (-)Ni2+ reaction reached completion at 5 hours and achieved a
maximum conversion of 38%, while the (+)Ni2+ reaction was much more successful,
reaching a conversion of 85% at the 9hr timepoint, (Figure 27b). Hydrolysis was
observed to increase for the (+)Ni2+ reactions, with a modest increase from <0.5% to 3.5%
with the addition of Ni2+.
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Figure 27. ESI-MS data for the C-terminal modification of sDARP with GGKDBCO. (A) Product conversion
for both reactions was estimated by ESI-MS. All data points represent the averaged of two trials,
with error bars corresponding to the full range of the data set. (B) ESI-MS spectra from the 9hr
timepoints of the (+)Ni2+ (bottom) and (-)Ni2+ (top) reactions (calculated molecular weights:
sDARPin = 15550 Da, sDARP(DBCO) = 15142 Da, hydrolyzed sDARP = 14613 Da).

We next evaluated whether the ligation product from the MASML reaction could
participate in a strain-promoted cycloaddition with a suitable azide reagent. Ultimately, a
one pot reaction sequence was developed that first involved the installation of DBCO
followed by a strain-promoted click reaction (Figure 28). As shown in Figure 28, a
MASML reaction between sDARP and one equivalent of GGK DBCO was performed in the
presence of Ni2+ as described above. After a 9 hour room temperature incubation, the
MASML reaction gave conversion to the DBCO conjugated product (78.5%, estimated by
ESI-MS). Two equivalents of azido 6-FAM were then added to the crude reaction mixture,
and the click reaction was tracked via ESI-MS. After 15min, the reactions saw a 63.5%
yield of the secondary ligation product (sDARP(6-FAM)click), which corresponds to an
80.0% consumption of the original ligation product, sDAPR(DBCO). The reaction reached
completion by 45min with a final product amount of 73.7% relative to the original,
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unmodified DARPin substrate. This was equal to a 91.9% conversion of the original
ligation product.
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Figure 28. ESI-MS data for the secondary ligation of sDARP with azido 6-FAM. (Top)
Reconstructed spectra of the reaction mixture after 9hrs of ligation, before addition of azido 6FAM. (Middle) Spectra from 15min after the addition of azido 6-FAM. (Bottom) Spectra from 2hrs
after the addition of azido 6-FAM. (Expected masses: sDARP = 15550 Da, sDARP(DBCO) =
15143 Da, sDARP(6-FAM)click = 15599 Da).

Given the high initial yield of DBCO-functionalized sDARP, and the near complete
conversion to the secondary click product, the one-pot experiment setup proved
successful. At this point, a simple affinity purification scheme could be applied to remove
unmodified sDARP still possessing the C-terminal His6-tag. While some unreacted
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sDARP(DBCO) would still remain, the final mixture would contain a greater than 90%
purity of sDARP(6-FAM)click.

4. Conclusions and Future Directions
The data in this thesis illustrate the significant enhancement provided by the
addition of nickel to sortase-mediated ligation reactions and demonstrate a broader range
of protein-based MASML applications than has been shown. Previously, high yields from
SML strategies were only achievable through the use of excess reagent or by significantly
altering the reagents and ligation site used for the sortase-mediated ligation. This work,
in conjunction with previous studies from the Antos group, shows that MASML is an
excellent alternative. MASML is compatible with a variety of protein targets (many of
which are in development as therapeutics), allows for a wide range of modifications, and
requires only the use of a simple solution additive (Ni2+) to improve ligation efficiency.
This work has a number of implications for the continued development of sortasebased methods for protein engineering. For instance, we have shown SrtA possesses
variable reagent affinity, even when the nucleophile base peptides or substrate C-termini
are similar. Given SML reactions are typically performed under conditions of excess
reagent, these trends of selectivity are not often apparent, but are obvious when neither
reagent is limiting. The ligation of sDARP and Cy3, for example, gave impressive yields
even in the absence of nickel, while reactions using the DBCO and 6-FAM appended
nucleophiles saw a doubling of yields with the addition of nickel (Figure 29). Interestingly,
we have shown that while some reagent-specificity is present when working at equimolar
concentrations, the enzyme’s selectivity is effectively eliminated with the use of MASML,
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with yields improved for all reactions (except those involving sAff) to greater than 80%,
even for those with low yields in the absence of Ni2+ (Figure 29).
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Figure 29. Final yields for all ligation pairings, with (-)Ni2+ reactions shown in light gray, and (+)Ni2+
shown in dark gray. Each bar represents the mean of two trials (except for the sMon reaction),
with error bars corresponding to the full range of the data set.

In addition, this work effectively demonstrates the compatibility of MASML with the
modification of antibody-alternative scaffolds, using the same sortase-ready C-terminal
sequence which has been used in previous studies involving the modification of
antibodies. The LPXTGGH6 sequence is a common motif in sortase-catalyzed ligations,
a recent example being the generation of antibody drug conjugates using SML to replicate
commercial conjugates, which were shown to have identical in vitro activity.27 SML has
also been applied to the fluorescent labeling of antibodies, as well as the generation of
crosslinked antibody-derived constructs to aide in overcoming the antibody resistance of
HIV-1.24 The data presented in this thesis demonstrate the effective improvement in
conjugate yields achievable with MASML in the context of antibody mimetics but can in
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theory be applied to antibodies as well. Sortase-ready antibodies have already been
established in previous literature, and so the application of this technique to those
systems would involve the simple addition of a cheap reagent, NiSO4, with no additional
alterations required for either the antibody substrates or the glycine nucleophileassociated modifications.
Furthermore, with a growing interest in molecules such as monobody, affibody,
and fynomer as smaller alternatives to full-sized antibodies, the ability to adapt
established SML methods for the generation of ADCs for use on non-antibody molecules,
is a promising direction for future studies. We have also shown while optimization may be
necessary, as was the case with monobody, even a slight excess of nickel in the reaction
mixture was sufficient to increase yields, showing the tolerance of this method to
adjustments for specific reagents and conditions.
Overall, this research also provides a basis for future MASML work in the context
of N-terminal modifications, as well as protein-protein ligations. The same protein targets
can be used as nucleophiles if modified to contain N-terminal glycines, and the panel of
modifications can be appended to synthetic substrates in a similar manner as the addition
to synthetic nucleophiles. Showing the applicability of MASML to these types of reactions
would help to provide a more complete foundation for enhancing future sortase-based
syntheses.
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5. Experimental
5.1 Protein Expression and Purification
Sequences of proteins used in this study:
SrtAStaph
MRGSSHHHHHHSSGLVPRGSHMQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPE
QLNRGVSFAEENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKY
KMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK
sDARP
MRGDLGKKLLEAARAGQDDEVRILMANGADVNAKDEYGLTPLYLATAHGHLEIVEVLL
KNGADVNAVDAIGFTPLHLAAFIGHLEIAEVLLKHGADVNAQDKFGKTAFDISIGNGNED
LAEILQKLNGGGGSGGGGSLPETGGHHHHHH
sAff (initiator methionine absent in purified protein)
VDNKFNKEMRNAYWEIALLPNLNNQQKRAFIRSLYDDPSQSANLLAEAKKLNDAQAPK
GGGGSGGGGSLPETGGHHHHHH
sMon
MRGSSVSSVPTKLEVVAATPTSLLISWDAPMSSSSVYYYRITYGETGGNSPVQEFTVP
YSSSTATISGLSPGVDYTITVYAWGEDSAGYMFMYSPISINYRTGGGGSGGGGSLPET
GGHHHHHH
sFyn
MRGSGVTLFVALYDYQADRWTDLSFHKGEKFQILDASPPGDWWEARSLTTGETGYIP
SNYVAPVDSIQGEQKLISEEDLGGGGSGGGGSLPETGGHHHHHH
sFh8 (initiator methionine absent in purified protein)
PSVQEVEKLLHVLDRNGDGKVSAEELKAFADDSKCPLDSNKIKAFIKEHDKNKDGKLDL
KELVSILSSGTSENLYFQGEEKKENDKEEGSMSSRIESLTIQEDAKEGVEDEEDGGGG
SGGGGSLPETGGHHHHHH
Plasmid Preparation. The pET-28a vector encoding SrtAStaph was obtained from
the Addgene plasmid repository (plasmid #51138). Expression vectors for sDARP, sMon,
sFyn, sAff, and sFh8 were obtained by commercial gene synthesis from ATUM, and were
prepared in the pD441-SR plasmid backbone.
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Expression and purification of substrate proteins. All protein substrates were
generated using the same general expression and purification scheme. Plasmids
containing the desired protein were transformed into BL21(DE3) chemically competent E.
coli cells via heat shock, and the cells were then plated onto LB-agar plates containing
100 µg/mL kanamycin. The plates were incubated at 37°C overnight. Single colonies were
collected from the plates and used to inoculate 50mL of LB broth containing kanamycin
at 100 µg/mL. These seed cultures were incubated with shaking at 37°C for approximately
18 hours. The full 50mL starter cultures were then added to 1L of sterile LB broth
containing 100 µg/mL kanamycin and incubated at 37°C with shaking. The 1L growths
were incubated until an OD600 of 0.8-0.9 was reached, at which point IPTG was added
(1mM final concentration) to induce protein expression. The cultures were then incubated
at 37°C with shaking for 3 hours. The cells were harvested by centrifugation at 4,629xg
for 10min.
Cell pellets were stored at -80°C until purification, at which point they were thawed
on ice in 30mL of lysis buffer (20mM Tris (pH 7.5), 150mM NaCl, 0.5mM EDTA). Once
thawed, lysozyme was added to a final concentration of 10 mg/mL and the cell
suspensions were shaken at room temperature for 1 hour. The resuspended cells were
sonicated twice, for 30 second intervals at 50% output. The lysate was clarified by
centrifugation at 39,375xg for 30min. The protein-containing supernatant was added to
5mL of His-Bind (Thermo-Fisher) Ni-NTA resin equilibrated in wash buffer (20mM Tris
(pH 7.5), 150mM NaCl, 20mM imidazole). The column was then flushed with 10 column
volumes of wash buffer. The remaining bound protein was eluted using 10mL of elution
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buffer (20mM Tris (pH 7.5), 150mM NaCl, 300mM imidazole), collected as two 5mL
fractions.
The gravity flow IMAC purified fractions were desalted using a 10mL Bio-Scale
Mini Bio-Gel desalting cartridge (Bio-Rad) on an NGC Quest 10 Plus FPLC system (BioRad) to remove imidazole. Desalting was achieved following the manufacturer’s protocol
using a mobile phase buffer consisting of 20mM Tris (pH 7.5) and 150mM NaCl at a flow
rate of 2 mL/min. The desalted proteins were then analyzed via ESI-MS to confirm protein
identity and to assess purity. In general, minor impurities were detected in most of the
gravity-flow purified protein stocks. To remove these impurities, a second IMAC
purification was performed using a 5mL Bio-Scale Mini IMAC affinity cartridge (Bio-Rad)
on an NGC Quest 10 Plus FPLC system (Bio-Rad). Briefly, the IMAC cartridge was first
equilibrated with 20mM Tris (pH 7.5), 150mM NaCl, and 20mM imidazole. Proteins were
then loaded onto the IMAC cartridge at a flow rate of 7 mL/min. A gradient elution of 20300 mM imidazole was then used to elute the target proteins (flow rate = 7 mL/min).
Fractions were then examined by ESI-MS and pure fractions were combined, then
desalted using the same desalting technique described previously (Appendix III). The
final storage buffer for all proteins consisted of 20mM Tris (pH 7.5) and 150mM NaCl.
Protein stocks were also analyzed by SDS-PAGE to confirm purity (Appendix III).
Determination of protein concentration. All protein concentrations were determined
using a NanodropTM ND-1000 spectrophotometer (Thermo Scientific) at 280nm. The
molar extinction coefficients used were 2980 cm-1 M-1 for sDARP, 8480 cm-1 M-1 for sAff,
1490 cm-1 M-1 for sFh8, 22460 cm-1 M-1 for sFyn, and 25900 cm-1 M-1 for sMon. Extinction
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coefficients were estimated from the individual protein sequences using ExPASy
ProtParam.

5.2 Peptide Synthesis
All reagents were acquired from the indicated commercial sources and used
without additional purification. HPLC purification and analysis were performed on a
Dionex Ultimate 3000 HPLC system (Thermo Scientific). ESI-MS was performed on an
expressionL CMS (Advion) attached to the above HPLC system. Analytical scale peptide
analyses were performed on a Kinetex® 2.6µm, C18 100Å LC column (100 x 2.1mm)
(C18, Phenomenex®) using the following method (Method A): H2O (5% acetonitrile, 0.1%
formic acid)/organic (MeCN, 0.1% formic acid) mobile phase. Flow rate = 0.4 mL/min.
Gradient = 5% organic (0.0-1.0 min), 5% organic to 90% organic (1.0-7.0 min), hold 90%
organic (7.0-9.0 min), 90% organic to 5% organic (9.0-9.1 min), equilibrate back to 5%
organic (9.1-12.0 min).
Peptides were purified on a Luna 5u, C18(2) 100Å column (250 x 10mm) (semiprep, Phenomenex®) using one of the following methods: (Method B): H2O (5%
acetonitrile, 0.1% formic acid)/organic (MeCN, 0.1% formic acid) mobile phase. Flow rate
= 4 mL/min. Gradient = 10% organic (0.0-2.0 min), 10% organic to 90% organic (2.0-12.0
min), hold 90% organic (12.0-14.0 min), 90% organic to 10% organic (14.0-14.1 min),
equilibrate back to 10% organic (14.1-17.0 min). (Method C): H2O (5% acetonitrile, 0.1%
TFA)/organic (MeCN, 0.1% TFA) mobile phase. Flow rate = 4 mL/min. Gradient = 20%
organic (0.0-2.0 min), 20% organic to 90% organic (2.0-15.0 min), hold 90% organic
(15.0-17.0 min), 90% organic to 20% organic (17.0-17.1 min), equilibrate back to 20%
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organic (17.1-19.0 min). (Method D): H2O (5% acetonitrile, 0.1% TFA)/organic (MeCN,
0.1% TFA) mobile phase. Flow rate = 4 mL/min. Gradient = 20% organic (0.0-2.0 min),
20% organic to 70% organic (2.0-15.0 min), 70% organic to 90% organic (15.0-15.1 min),
hold 90% organic (15.1-17.0 min), 90% organic to 10% organic (17.0-17.1 min),
equilibrate back to 20% organic (17.1-19.0 min).
Solid-phase peptide synthesis. The base peptides (Fmoc-GGK and Fmoc-GGKY)
for all nucleophiles was synthesized on a 0.2mmol scale using rink amine MBHA resin
(AnaSpec Inc.). The resin was first washed/swollen in NMP. Deprotection was then
performed by treatment with 20% piperidine in NMP (10mL, 2x, 10min each) followed by
washes with pure NMP (10mL, 3x, 5min each) to remove cleaved Fmoc. The deprotected
resin was then treated with a coupling mixture containing an Fmoc-protected amino acid
(Chem-Impex Int’l Inc., 0.6mmol), HBTU (Chem-Impex Int’l Inc., 0.6mmol) and DIPEA
(1mM) solvated in ~3mL of NMP. Coupling occurred at room temperature with shaking
for 1 hour or overnight. Unreacted components were washed from the resin mixture using
NMP (10mL, 3x, 5min each). Additional amino acids were added using the same method
of deprotection, washing, and coupling.
The base peptides were not subjected to Fmoc deprotection before cleavage from
the resin, so as to leave only one nucleophilic amine for later modification. Cleavage was
achieved by first washing the resin with DCM (10mL, 3x, 5min each), then incubating with
cleavage solution (95/2.5/2.5 TFA/ddH2O/TIPS) for 30min (2x, 5 mL each). After each
incubation period, the cleavage solution was drained and collected. TFA was removed
via rotary evaporation. The remaining peptide solution was precipitated by drop-wise
addition to dry ice-chilled diethyl ether. The precipitated peptides were then pelleted by
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centrifugation at 4,696xg for 5min. Supernatant was removed, and pelleted peptides were
dried under vacuum overnight. The crude peptides were then resolubilized in NMP to a
final concentration of approximately 100 mg/mL.
Modification of base-peptide with desired functional group. Once the base peptides
had been generated, they were used without further purification to generate the
nucleophile library used in this thesis. Modifications were installed via reaction of the base
peptides (Fmoc-GGK or Fmoc-GGKY) with activated ester derivatives of the desired
modifications. Ligation mixtures were prepared on a scale to yield 3mg of the end product
(15mg, in the case of GGKdPEG2000Y) using a 2x molar excess of the base peptide relative
to the activated ester. The base peptide for all nucleophiles was Fmoc-GGK, except in
the case of GGKdPEG2000Y, which was generated using Fmoc-GGKY for quantification
purposes as PEG does not have a unique absorbance maximum. The ligation process
was tracked by HPLC and ESI-MS using a C18 column and Method A. When no more
unligated modification could be detected, piperidine was added to a final concentration of
20% (v/v) to remove the N-terminal Fmoc group. The reaction was again observed using
HPLC and ESI-MS (Method A) until deprotection was complete (see Appendix I for
example spectra).
Synthesis of GGK6-FAM. Fmoc-GGK (9.72 µmol), NHS-6-FAM (AnaSpec,
4.86µmol), and DIPEA (29.2µmol) were combined in NMP (100µL total volume). The
reaction was complete after 30 min as determined by ESI-MS (expected mass for FmocGGK6-FAM [M+H]+ = 840.3 Da, observed mass = 840.3 Da). Piperdine (25µL, 20% v/v)
was then added to remove the Fmoc group. Deprotection was monitored by ESI-MS, and
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determined to be complete by 30 min (expected mass for GGK6-FAM [M+H]+ = 618.2 Da,
observed mass = 618.3 Da).
Synthesis of GGKCy3. Fmoc-GGK (8.58µmol), NHS-Cy3 (Lumiprobe, 4.29µmol),
and DIPEA (25.7µmol) were combined in NMP (100µL total volume). The reaction was
complete after 60 min as determined by ESI-MS (expected mass for Fmoc-GGKCy3
[M+H]+ = 921.5 Da, observed mass = 921.8 Da). Piperdine (25 µL, 20% v/v) was then
added to remove the Fmoc group. Deprotection was monitored by ESI-MS, and
determined to be complete by 30 min (expected mass for GGKCy3 [M+H]+ = 698.9 Da,
observed mass = 698.7 Da).
Synthesis of GGKDEAC. Fmoc-GGK (11.9µmol), NHS-DEAC (Sigma Life Science,
5.97µmol), and DIPEA (35.82µmol) were combined in NMP (100µL total volume). The
reaction was complete after 90 min as determined by ESI-MS (expected mass for FmocGGKDEAC [M+H]+ = 725.3 Da, observed mass = 725.3 Da). Piperidine (25 µL, 20% v/v)
was then added to remove the Fmoc group. Deprotection was monitored by ESI-MS, and
determined to be complete by 90 min (expected mass for GGKDEAC [M+H]+ = 503.3 Da,
observed mass = 503.3 Da).
Synthesis of GGKDBCO. Fmoc-GGK (11.0µmol), NHS-DBCO (Conju-Probe,
5.49µmol), and DIPEA (32.9µmol) were combined in NMP (100µL total volume). The
reaction was complete after 25 min as determined by ESI-MS (expected mass for FmocGGKDBCO [M+H]+ = 769.3 Da, observed mass = 769.3 Da). Piperidine (25 µL, 20% v/v)
was then added to remove the Fmoc group. Deprotection was monitored by ESI-MS, and
determined to be complete by 50 min (expected mass for GGKDBCO [M+H]+ = 547.3 Da,
observed mass = 547.3 Da).
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Synthesis of GGKdPEG2000Y. Fmoc-GGKY (10.7 µmol), TFP-dPEG2000 (Quanta
Biodesign Lmt., 5.33 µmol), and DIPEA (32.0 µmol) were combined in NMP (100 µL total
volume) and analyzed via ESI-MS every 15 min. The expected [M+2H]2+ for FmocGGKdPEG2000Y was 1409.3 Da, and the observed mass was 1409.7 Da. The ligation
reached completion at 90min, at which point piperidine (25µL, 20% v/v) was added to
remove the Fmoc group. Deprotection was complete by 60min as determined by ESI-MS.
The expected molecular weight for GGKdPEG2000Y was 2594.4 Da and was observed as
[M+3H]3+ (expected: 866.4 Da, observed: 866.3 Da) and as a number of ammonium
adducts: [M+1H+2NH4]3+ (expected: 877.7 Da, observed: 877.6 Da), [M+2H+NH4]3+
(epected: 872.0 Da, observed: 871.9 Da), [M+2H+2NH4]4+ (expected: 658.5 Da,
observed: 658.5 Da), [M+3H+NH4]4+ (expected: 654.3 Da, observed: 654.4 Da).
Nucleophile Purification. All peptide nucleophiles were purified by HPLC prior to
use in sortase-mediated ligation reactions. Product peaks were tracked at the λmax for the
respective functional groups, and separations were achieved using a semi-prep column
with HPLC Methods B, C, or D (Table 1). Pure fractions were pooled and MeCN and
formic acid were removed from the purified peptide solution by rotary evaporation. The
remaining peptide solution was frozen over dry-ice and lyophilized. Dry peptides were
resolubilized in DMSO, water, or a mixture of both depending on the solubility of the
modification (Table 1). Final stock concentrations were determined using a Nanodrop TM
ND-1000 spectrophotometer (Thermo Scientific) at the λmax for the modification and using
the appropriate molar extinction coefficients listed below in Table 1. For most
applications, stocks were diluted to approximately 1mM for use in reactions and
underwent final ESI-MS and UV-Vis analysis to confirm identity and purity (Appendix II).
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Table 1. Purification and quantification parameters for the nucleophile library.

Modification

λmax

6-FAM
Cy-3
DEAC
DBCO
dPEG2000*

495 nm
555 nm
429 nm
309 nm
280 nm

Molar Extinction
Purification
Final Solvent
-1
-1
Coefficient (M cm )
Method
Composition
75,000
D
DMSO
150,000
C
DMSO
46,800
B
5:2 ddH2O:DMSO
12,000
B
5:1 ddH2O:DMSO
1,280
B
ddH2O

*(quantified using the Tyr present in base peptide)

5.3 General procedure for Sortase Catalyzed Ligations
Analytical scale separations of full-sized proteins for ESI-MS were performed using
an Aeris™ 3.6µm, WIDEPORE C4 200Å LC column (100 x 2.1mm) (C4, Phenomenex®).
LC-ESI-MS analyses performed on the C4 used the following method (Method E): H2O
(5% acetonitrile, 0.1% formic acid) / organic (MeCN, 0.1% formic acid) mobile phase.
Flow rate = 0.3 mL/min. Gradient = 10% organic (0.0-0.5 min), 10% organic to 90%
organic (0.5-7.0 min), hold 90% organic (7.0-8.0 min), 90% organic to 10% organic (8.08.1 min), equilibrate back to 10% organic (8.1-13.25 min).
All C-terminal SML and MASML reactions, with the exception of the ligation of
sMon and GGKDEAC, performed for this thesis used the same basic reaction composition
listed in Table 2 and were performed at room temperature unless otherwise indicated.
Reactions were run on 100µL scale, and all reactions also contained 10% (v/v) 10x
sortase reaction buffer (500mM Tris (pH 7.5), 1.5M NaCl, and 100mM CaCl2). Reactions
were analyzed every hour via ESI-MS, using the C4 column and HPLC Method E. The
mass range used was 500-1800 Da. Raw ESI-MS data from each timepoint was
processed using the following three-step protocol: the raw chromatogram data was first
exported from Advion Data Expression (Ver 3.0) as .CDF files, and reconstructed in
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MNova (Ver 10.0). The mass peak corresponding to the unmodified substrate and ligation
product was highlighted and the spectra extracted. These spectra were converted to text
files and opened in Analyst® (Ver 1.4) to reconstruct the mass graph (maximum entropy
algorithm). Product conversion was then calculated using area-under-the-curve for the
starting material, ligation product, and hydrolysis product. This was performed at each
timepoint and averaged across duplicate trials.
Table 2. Reaction concentrations of each reagent in the C-terminal SML/MASML reactions (using
equimolar amounts of substrate and nucleophile) completed in this study.

Reagent
Substrate
Nucleophile
NiSO4 (Ni2+)
SrtAStaph

(+)Ni2+
50 µM
50 µM
200 µM
10 µM

(-)Ni2+
50 µM
50 µM
0 µM
10 µM

The SML/MASML of sMon and GGKDEAC was adjusted to account for the
insolubility of monobody is the presence of excess Ni2+ (Table 3). As in the case of other
targets, sMon reactions were run on 100µL scale, and all reactions contained 10% (v/v)
10x sortase reaction buffer (500mM Tris (pH 7.5), 1.5M NaCl, and 100mM CaCl2). The
reactions were allowed to proceed at room temperature, with 20µL aliquots collected at
0, 6, 12, and 24hrs. These samples were quenched using 6.67µL of a 4X DTT-containing
SDS-PAGE loading buffer, and a second 24hr aliquot was quenched with an equal
volume of MeCN (0.1% formic acid). The loading buffer-quenched samples were
analyzed by SDS-PAGE (10µL loading volume). ESI-MS analysis was performed on the
MeCN quenched 24hr samples, using HPLC Method E and a 500-1800 Da mass range.
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Table 3. Reaction concentrations of each reagent in the C-terminal modification of sMon with
GGKDEAC.

(+)Ni2+/
(-)Ni2+/
(+)DMSO (+)DMSO
Substrate
50 µM
50 µM
Nucleophile
50 µM
50 µM
2+
NiSO4 (Ni ) 100 µM
0 µM
DMSO
20%
20%
SrtAStaph
10 µM
10 µM
Reagent

(-)Ni2+/
(-)DMSO
50 µM
50 µM
0 µM
0%
10 µM

Optimization of sDARP and GGKDEAC ligation reaction. These reactions were run
in duplicate and analyzed via the method outlined above. sDARP (50µM) was combined
with varying amounts of GGKDEAC: 1x (50µM), 2x (100µM), 3x (150µM), 5x (250µM), or
20x (1mM) in the absence of Ni2+ additive. Each reaction was run in duplicate on 100 µL
scale and analyzed by ESI-MS. All reactions contained 10% (v/v) 10x sortase reaction
buffer (500mM Tris (pH 7.5), 1.5M NaCl, and 100mM CaCl2).
Combined MASML and Bioorthogonal Ligation Reaction. sDARP (50µM) was
combined with GGKDBCO (50µM) and SrtAStaph (10µM) in the presence or absence of Ni2+
(from NiSO4, 200µM). The reaction was performed on a 100 µL scale and contained 10%
(v/v) 10x sortase reaction buffer (500mM Tris (pH 7.5), 1.5M NaCl, and 100mM CaCl 2).
The reaction mixture was examined after 9 hours by ESI-MS. After the initial 9hr ligation
period, azido 6-FAM was directly added to the reaction mixture (1.09 µL of a 450 µM
DMSO stock solution, 100µM final concentration of azido 6-FAM). The biorthogonal
ligation reaction was then monitored by ESI-MS every 15 min, over the course of 2 hours.
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7. Appendix
7.1 Appendix I: Representative Mass Spectra from the Synthesis of GGKDBCO

A

1
1

2

2

ESI-MS TIC from the ligation step, 25min after initiation. Peak 1 corresponds to unreacted FmocGGK, the base peptide for the nucleophile (expected: 482.2 Da, observed: 482.3 Da). Peak 2
represents the conjugated product (expected: 769.3 Da, observed: 769.3 Da).

B

3
3

4

4

ESI-MS TIC from the deprotection step, 25min after adding piperidine. Peak 3 corresponds to
deprotected GGKDBCO (expected: 547.3 Da, observed: 547.3 Da). Peak 4 represents hydrolyzed
DBCO (expected: 306.1 Da, observed: 306.1 Da).
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C
5
5

ESI-MS TIC of the purified GGKDBCO stock at reaction concentration (50µM). Peak 5 corresponds
to the final product, GGKDBCO (expected: 547.3 Da, observed: 547.2 Da).

64

7.2 Appendix II: Analytical RP-HPLC and ESI-MS Data for Peptide Nucleophiles

UV-Vis analysis of GGK(6-FAM) stock at 50µM. (Top) Absorbance at 210nm, with nucleophile
structure and ESI-MS data reported. (Bottom) Absorbance at the λmax of the nucleophile.
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UV-Vis analysis of GGK(Cy3) stock at 50µM. (Top) Absorbance at 210nm, with nucleophile
structure and ESI-MS data reported. (Bottom) Absorbance at the λmax of the nucleophile.
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UV-Vis analysis of GGK(DEAC) stock at 50µM. (Top) Absorbance at 210nm, with nucleophile
structure and ESI-MS data reported. (Bottom) Absorbance at the λmax of the nucleophile.
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UV-Vis analysis of GGK(DBCO) stock at 50µM. (Top) Absorbance at 210nm, with nucleophile
structure and ESI-MS data reported. (Bottom) Absorbance at the λmax of the nucleophile.
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UV-Vis analysis of GGK(dPEG2000) stock at 50µM. (Top) Absorbance at 210nm, with nucleophile
structure and ESI-MS data reported. (Bottom) Absorbance at the λmax of the nucleophile.
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7.3 Appendix III: Analytical ESI-MS and SDS-PAGE Data for Protein Substrates

ESI-MS analysis of SrtAStaph stock. (Top) Reconstructed mass graph. (Bottom) Charge ladder,
with main peak labeled with mass and charge state. Expected mass: [M] = 19048 Da, [M+24H]24+
= 794.7 Da.
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ESI-MS analysis of sDARP stock. (Top) Reconstructed mass graph. (Bottom) Charge ladder, with
main peak labeled with mass and charge state. Expected mass: [M] = 15550 Da, [M+16H]16+ =
972.9 Da.
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ESI-MS analysis of sAff stock. (Top) Reconstructed mass graph. (Bottom) Charge ladder, with
main peak labeled with mass and charge state. Expected mass: [MHis6] = 8714 Da, [MHis1] = 8028
Da, [MHis6+11H]11+ = 793.2 Da, [MHis1+8H]8+ = 1004.5 Da.
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ESI-MS analysis of sMon stock. (Top) Reconstructed mass graph. (Bottom) Charge ladder, with
main peak labeled with mass and charge state. Expected mass: [M] = 13018 Da, [M+10H]10+ =
1302.8 Da.
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ESI-MS analysis of sFyn stock. (Top) Reconstructed mass graph. (Bottom) Charge ladder, with
main peak labeled with mass and charge state. Expected mass: [M] = 10907 Da, [M+Ac] = 10949
Da, [M+11H]11+ = 992.5 Da.
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ESI-MS analysis of sFh8 stock. (Top) Reconstructed mass graph. (Bottom) Charge ladder, with
main peak labeled with mass and charge state. Expected mass: [M] = 14636, [M+Ac] = 14678
Da, [M+15H]15+ = 976.7 Da, [M+Ac+19H]19+ = 773.5 Da.
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SDS-PAGE analysis of sFh8 (50µM), on a gel containing 15% acrylamide.
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SDS-PAGE analysis of SrtA and sMon stocks (10µM and 50µM, respectively), on a gel containing
an acrylamide gradient.
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SDS-PAGE analysis of sDARP, sAff and sFyn stocks (50µM each), on a gel containing 15%
acrylamide.
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